• Excess mortality
  • Trending

NOS: "Even the producer advises against ivermectin"

by Anton Theunissen | Dec 22 2021, 4:12 pm

← Stefan: A different approach is quite possible! Week 50 2021: Peak vaccination deaths seems to be over (for a while) →
reading time

[this article has a more recent version]

All the way to the court, top doctors and doctors beg to lift the ban on ivermectin – and always in vain, again this week. Hardcore anti-quacks vote against: It really has to come from the pharmaceutical companies, otherwise it can't be trusted. And those pharmaceutical companies say 'no'. Why is that? Already discussed earlier but again topical.

The NOS news concludes crystal clear that ivermectin does not work, that even the producer of ivermectin says that it does not work.

"Even the producer (Merck, ed.) says ivermectin does not work against Covid-19."

Bouncer of the arguments in the boycott campaign last night 21 Dec. 2021 in the NOS news.

How about that?

Merck is a healthy company and it's their responsibility to keep it that way. If a producer like Merck sees the opportunity to become a co-producer of a vaccine to be rolled out worldwide (semi)annually, then it would be bad entrepreneurship to promote a pill instead whose patent has long since expired. That means competition and therefore suboptimal profit margins. That's not the business model. It is all about the unique patent ownership because that gives the exclusive right and so interesting margins can be realized in negotiations with governments, insurers and healthcare institutions.

Now this was an emergency vaccine that would be allowed under very strict conditions, possibly because of the emergency situation. An EUA (Emergency Use Authorization) becomes difficult to impossible if other medication is already available. Ivermectin could therefore throw a spanner in the works. Shareholders would ask questions. See below the development in official press releases from ivermectin producer Merck.

Merck discourages Ivermectin – timeline. Pay attention to the dates 👇

I have cited these Merck press releases before. Given current events, thanks to the NOS news and ongoing court cases, I repeat them here:

January 25, 2021 6:45 am ETKENILWORTH, NJ – (BUSINESS WIRE) – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the company is halting development of its SARS-CoV-2/COVID-19 vaccine candidates.

Feb. 4, 2021 11:45 a.m. ETKENILWORTH, NJ – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today confirmed its position regarding the use of ivermectin during the COVID-19 pandemic. We continue to carefully examine the findings of all available and emerging studies of ivermectin for the treatment of COVID-19 for evidence of efficacy and safety. It is important to note that our analysis to date has shown:

  • No scientific basis for a possible therapeutic effect against COVID-19 from preclinical studies;
  • No meaningful evidence of clinical activity or clinical efficacy in patients with COVID-19 disease, and;
  • A worrying lack of safety data in most studies.

2 March 2021 – Merck/MSD gaat helpen bij de productie van het ‘Leidse vaccin’ van Janssen. Op 2 maart 2021 kondigden we onze samenwerking met Johnson & Johnson (het moederbedrijf van Janssen) aan, waarbij we in de VS productiecapaciteit ter beschikking stellen.

Merck's objections can be questioned:

  • There is indeed a scientific basis for a possible effect against Covid-19. Sufficient to justify a large-scale investigation. See for example https://pubmed.ncbi.nlm.nih.gov/34145166/ (recent study; even at that time there was already an overwhelming amount of signals, see the heading metastudies.)
  • "No meaningful evidence". This swept everything off the table as soon as it does not meet the research standards that only the pharmaceutical companies themselves can afford. That is precisely why there is a need for capital to organize a large study.
  • "A worrying lack of safety data" is reason for Merck to discourage a drug of which they have already sold many billions of doses and distributed them for free, with minimal side effects. Less than several worldwide used painkillers for example (see videos by John Campbell).

Dr. Satoshi Ōmura, the discoverer of the Nobel Prize-winning ivermectin, has asked Merck to set up a trial. Merck refused. (More info and interpretation in this message from biznews.com.)

Merck's new Covid pill, Molnupiravir, is admittedly less effective but patented. This also applies to the new Pfizer pill Paxlovid, which has (partly) the same mechanism as ivermectin.

Meta-studies

Below are two websites that keep overviews of almost all ivermectin studies. There are also negative studies, for example among ICU patients. These "Late treatment studies" often give a bad picture. It has never been claimed that ivermectin is the panacea that cures the seriously ill. Yet it is tried out that way. The pre-selection of subjects (treated/placebo) is also sometimes problematic.

https://ivmmeta.com/

https://c19ivermectin.com/

Videos

Dr. John Campbell on Paxlovid vs ivermectin, 22 minutes:

Dr. John Campbell on Molnupiravir vs ivermectin, 29 minutes:

Sweet junk may strangely enough be used against Covid, while we are still dealing with largely obese Covid patients. ivermectin is strictly prohibited. I really wonder what's worse for those people.

← previous post Next post →
Related reading pleasure:
  • Click Previous Post (or Next)

amnesty Anne Frank antibiotics Babies Bioweapons conspiracy theory

fraud ionization Mass formation Un Lawsuits thrombosis

WOO ChatGPT Causes John Ukraine PeterSweden

RKI vitaminD cardiovascular Germany filosofie obfuscation

Parliamentary inquiry sociology Wob foreign country journalism nocebo

opinion alijst IC Badbatches OUR Pfizer

responsibility disinformation narrative praise Wynia Level

Children Public health Side effects infection scientific integrity keulemans

vaccine communication science vaccination excess mortality statistics

media science corruption aerosols lableak CBS politics

research mdhaero ivermectin Measures Wuhan paradogma

hve Australia Vaccination readiness Government information NRC women

Fauci Post-Covid norm mortality lockdowns Burkhardt Baseline

UK rivm Excess mortality debate Gupta effectiveness censorship

asmr Mortality Monitor privacy Repopulation Koopmans Japan

data Bulgaria safety Spike qaly motive

Lareb Hotels heart failure ethics variegated bhakdi monkeypox

Anti-VAX fear

Views (inst:8-10-'21): 1.652
← Stefan: A different approach is quite possible! Week 50 2021: Peak vaccination deaths seems to be over (for a while) →

Would you like a notification e-mail with each new article?

Thanks for your interest!
Some fields are missing or incorrect!
Bijdragen aan virusvaria mag. Klik en vul zelf het bedrag in
👇
Iets bijdragen? Graag! Klik hier.
👍

Foute onderzoekers vegen straatje schoon met noviteit: het ‘Healthy Vaccinee Effect’

jun 14, 2025

Sterfte naar doodsoorzaak: nieuwvormingen (kanker)

jun 12, 2025

En de winnaar is inderdaad: Bulgarije!

jun 8, 2025

Sterfte naar doodsoorzaak: hart- en vaatziekten

mei 30, 2025

And the winner will be...

mei 27, 2025

Cracked Counter Noise Bell

May 24, 2025

Alarmism as a cover-up

mei 14, 2025

The mystery of the lost forms

May 11, 2025

Preferred context – illustrated and with example

May 3, 2025

Een omgekeerd Agemaatje van Grok (Watch till the end!)

mei 1, 2025

We don't really get older but on average we do

Apr 25, 2025

ChatGPT on AI and truth distortion

apr 21, 2025

« Previous Page

Iets bijdragen? Graag! Klik hier.

Translation


© Contact Anton Theunissen
Wij gebruiken een cookiebar op onze website om u te informeren dat wij het gebruik analyseren. Wij gebruiken cookies niet voor marketingdoeleinden. (Google respecteert de privacy wetten.)
OK
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDuurBeschrijving
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
OPSLAAN & ACCEPTEREN
Aangedreven door CookieYes Logo